The ferroptosis-related LncRNA CASC9 reveals its potential as a diagnostic and prognostic biomarker in esophageal squamous cell carcinoma
- 1Department of Oncology, The Affiliated Suqian Hospital of Xuzhou Medical University
- 2Department of Oncology, Cancer Institute, Jiangyin Hospital, Jiangyin People’s Hospital, Jiangyin Clinical College of Xuzhou Medical University, Xuzhou Medical University, Nantong University
- 3Department of Oncology, Taizhou People’s Hospital, Nanjing University of Chinese Medicine
Abstract
This study aimed to investigate the role of ferroptosis-related long non-coding RNA CASC9 in the carcinogenic process of esophageal squamous cell carcinoma and evaluate its clinical diagnostic and prognostic value. LncRNA microarray screening was performed to identify differentially expressed genes in ESCC tissues. CASC9 expression was validated in 150 paired ESCC tissues, precancerous lesions, and cell lines by qRT-PCR. The correlation between CASC9 expression and clinicopathological characteristics as well as survival outcomes was analyzed. In vitro functional assays were conducted to examine the effects of CASC9 on ESCC cell proliferation, apoptosis, invasion, and migration. The role of CASC9 in ferroptosis was explored by detecting GSH, MDA, and ROS levels. CASC9 was significantly overexpressed in 92.7% of ESCC tissues (mean 11-fold upregulation), showing stepwise elevation during disease progression (normal mucosa→LGIN→HGIN→invasive carcinoma); High CASC9 expression correlated significantly with depth of invasion (P = 0.001) and clinical stage (P = 0.033), serving as an independent risk factor for overall survival (HR = 1.550, P = 0.026); Plasma CASC9 levels were significantly elevated in ESCC patients and markedly decreased at 14 and 30 days postoperatively. CASC9 knockdown markedly suppressed ESCC cell proliferation, invasion, and migration while promoting apoptosis. Reduced GSH and MDA/ROS accumulation indicate that CASC9 regulates ESCC progression via the ferroptosis pathway. In combination with clinicopathological features, a nomogram based on the gene signature presented strong predictive power and risk stratification for ESCC. CASC9 functions as an oncogenic lncRNA that promotes ESCC progression by modulating ferroptosis, representing a promising early diagnostic biomarker, prognostic predictor, and therapeutic target.
Related
- LRRC8C is a potential diagnostic and prognostic biomarker associated with immune modulation in lower-grade glioma
- Multi-omics profiling uncovers diagnostic biomarker panel, progression-associated subtypes, and prognostic signature in pediatric mitochondrial disease
- Pan-Cancer Analysis Identifies LUC7L2 as a Prognostic Biomarker and Potential Functional Regulator of Prostate Cancer Progression
- Pan-cancer analysis identifies ANGPT4 as a potential prognostic biomarker associated with the tumor microenvironment in kidney renal clear cell carcinoma
- Multi-omics integration identifies serum FTL as a novel diagnostic biomarker for esophageal squamous cell carcinoma
BibTeX
@article{yaoyao2026ferroptosisrelated,
title = {{The ferroptosis-related LncRNA CASC9 reveals its potential as a diagnostic and prognostic biomarker in esophageal squamous cell carcinoma}},
author = {Wu Yaoyao and Lin Qingfeng and Huang Liyou and Xu Lu and Huang Junxing and Liu Zihao},
journal = {Scientific Reports},
year = {2026},
month = jul,
doi = {10.1038/s41598-026-63321-5},
url = {https://doi.org/10.1038/s41598-026-63321-5},
note = {CC BY},
}
RIS
TY - JOUR
TI - The ferroptosis-related LncRNA CASC9 reveals its potential as a diagnostic and prognostic biomarker in esophageal squamous cell carcinoma
AU - Wu Yaoyao
AU - Lin Qingfeng
AU - Huang Liyou
AU - Xu Lu
AU - Huang Junxing
AU - Liu Zihao
PY - 2026
DA - 2026/07/01
JO - Scientific Reports
DO - 10.1038/s41598-026-63321-5
UR - https://doi.org/10.1038/s41598-026-63321-5
AB - This study aimed to investigate the role of ferroptosis-related long non-coding RNA CASC9 in the carcinogenic process of esophageal squamous cell carcinoma and evaluate its clinical diagnostic and prognostic value. LncRNA microarray screening was performed to identify differentially expressed genes in ESCC tissues. CASC9 expression was validated in 150 paired ESCC tissues, precancerous lesions, and cell lines by qRT-PCR. The correlation between CASC9 expression and clinicopathological characteristics as well as survival outcomes was analyzed. In vitro functional assays were conducted to examine the effects of CASC9 on ESCC cell proliferation, apoptosis, invasion, and migration. The role of CASC9 in ferroptosis was explored by detecting GSH, MDA, and ROS levels. CASC9 was significantly overexpressed in 92.7% of ESCC tissues (mean 11-fold upregulation), showing stepwise elevation during disease progression (normal mucosa→LGIN→HGIN→invasive carcinoma); High CASC9 expression correlated significantly with depth of invasion (P = 0.001) and clinical stage (P = 0.033), serving as an independent risk factor for overall survival (HR = 1.550, P = 0.026); Plasma CASC9 levels were significantly elevated in ESCC patients and markedly decreased at 14 and 30 days postoperatively. CASC9 knockdown markedly suppressed ESCC cell proliferation, invasion, and migration while promoting apoptosis. Reduced GSH and MDA/ROS accumulation indicate that CASC9 regulates ESCC progression via the ferroptosis pathway. In combination with clinicopathological features, a nomogram based on the gene signature presented strong predictive power and risk stratification for ESCC. CASC9 functions as an oncogenic lncRNA that promotes ESCC progression by modulating ferroptosis, representing a promising early diagnostic biomarker, prognostic predictor, and therapeutic target.
SN - 2045-2322
ER -